Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population

• Published in: Scientific reports Vol. 12; no. 1; pp. 14681 - 11
• Main Authors: Roy, Dipa, Rahman, Md. Mosfequr, Chaity, Arnaba Saha, Reza, Md. Abu, Haque, Ariful
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 29.08.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250; 631/326; Asthma; COVID-19; Dosage; Drug dosages; Humanities and Social Sciences; Immune system; Immunization; multidisciplinary; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Vaccines
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-18302-9

Development of effective vaccines have been immensely welcomed by the world to prevent the transmission of SARS-CoV-2. However, the duration and clinical implications of antibody-mediated natural immunity in SARS-CoV-2 have not been adequately elucidated alongside some other immune system transforming factors. In a cohort study, we measured NAb titer following the 2nd immunization dosage of the CoviShield (AZD1222) vaccine . The enzyme-linked immunoassay was used to look for SARS-CoV-2—specific NAb. We measured NAb at 30 days after the 2nd dosage of immunization and > 96% titer was detected in 42.9% of subjects, but only 5.1% of subjects retained the same level after 180 days. The median NAb titer dropped significantly, from 92% at 30 days to 58% at 180 days (p < 0.001). Besides, there were significant differences observed in NAb titer after 180 days by age, sex, COVID-19 infection, tobacco use, and asthma patients. However, SARS-CoV-2 infection along with two dosages of immunization upheld NAb titer ( p  < 0.001) even at the end of the study period.